Amisulpride – Mechanism of Action | Psychopharmacology | Clinical Application
Amisulpride is a synthetic substituted benzamide compound that is approved in Europe and Australia for the treatment of psychosis and schizophrenia. Amisulpride (Solian) is available in 50 mg and 200 mg tablets and is used to treat positive and negative symptoms of acute and chronic schizophrenia in adults.
Furthermore, clinical trials have also shown that amisulpride has antidepressant properties in both schizophrenia [Kim et al. 2007] and mood disorders [Montgomery 2002] and that it improves cognition with notable effects on the domains of attention, executive function, and working memory. [Mortimer et al. 2007]
Andersen, H. G., Raghava, J. M., Svarer, C., Wulff, S., Johansen, L. B., Antonsen, P. K., … & Pinborg, L. H. (2020). Striatal Volume Increase After Six Weeks of Selective Dopamine D2/3 Receptor Blockade in First-Episode, Antipsychotic-Naïve Schizophrenia Patients. Frontiers in Neuroscience, 14, 484.
Krause, M., Zhu, Y., Huhn, M., Schneider-Thoma, J., Bighelli, I., Nikolakopoulou, A., & Leucht, S. (2018). Antipsychotic drugs for patients with schizophrenia and predominant or prominent negative symptoms: a systematic review and meta-analysis. European archives of psychiatry and clinical neuroscience, 268(7), 625-639.